Antagonism of Prostanoid‐Induced Vascular Contraction by 13‐Azaprostanoic Acid (13‐APA)

P. Horn,J. Kohli,G. Lebreton,D. Venton
DOI: https://doi.org/10.1097/00005344-198407000-00009
IF: 3.271
1984-07-01
Journal of Cardiovascular Pharmacology
Abstract:Isometric contractions in vitro of helically eut strips of canine mesenteric arteries (O.D. = 0.6–1 mm) were recorded in the presence of 10 μM indomethacin. PGF2α PGE2, U-46619 (TXA2 mimetic), norepinephrine, 5-hydroxytryptamine, and KCl produced dose-related contractions. The EC50 values of the prostanoids in the control period were: PGF2α, 7.3 ± 0.7 × 10−7M; PGE2, 2.1 ± 0.2 × 10−6M; and U-46619, 4.1 ± 1.0 × 10−10M. Exposure to 13-azaprostanoic acid (13-APA), 5 × 10−5M and 2 x 10−4M, for 20 min caused parallel and doserelated shifts to the right of the doseresponse curves generated by ail three prostanoids without affecting the contractile responses to KCl, norepinephrine, or 5-hydroxytryptamine or relaxation induced by PGI2. 13-APA, at the concentrations used, had no agonist activity. Small contractions (10–15%) seen on the addition of 13-APA to the baths were found to be related to the alcohol content of the solvent. Dose ratios (with/without antagonist) at the EC50 level were found to be: in the presence of 5 × 10−5M 13-APA PGF2α, 2.7 ± 0.3; PGE2, 3.5 ± 0.9; U-46619, 5.2 ± 0.9; in the presence of 2 × 10−4M 13-APA PGF2α, 17.1 ± 3; PGE2, >50; and U-46619, 23.3 ± 5.7. Thus, 13-APA is a specific antagonist of these prostanoids with no agonist activity of its own.
What problem does this paper attempt to address?